YUMANITY

[Grasss1973]

Don't know if this has already been posted, but this is very exciting. Up until recently, there has been very little translation from the lab to the clinic. A viable treatment for humans is a ways off but this should truly give us all hope !

Yumanity demonstrates pre-clinical proof of concept for YTX-7739 in Parkinson’s

Mar. 09, 2021 4:12 PM ETYumanity Therapeutics, Inc. (YMTX)By: Dulan Lokuwithana, SA News Editor

Yumanity Therapeutics (NASDAQ:YMTX) has announced pre-clinical data to show the proof of concept of its lead asset YTX-7739 in a Parkinson’s disease ("PD") mouse model.

YTX-7739 is a small molecule investigational therapy that can penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase ("SCD"), which is expected to play a vital role in neurotoxicity arising from the alpha-synuclein protein.

Alpha-synuclein protein is believed to be a major cause of Parkinson’s disease and related neurodegenerative disorders.

After four months of YTX-7739 oral dosing, the study has indicated the prevention of motor function deficits in the diseased mice compared to placebo.

YTX-7739 in the brain has reached a level that engaged and inhibited SCD activity consistent with in vitro studies.

Compared to controls, multiple biochemical measures of α-synuclein pathology including the levels of pathological α-synuclein, a strong risk factor for Parkinson’s disease, showed a significant improvement in mice with YTX-7739.

Mice treated with YTX-7739 were shown to have enhanced survival of dopaminergic neurons, which selectively die in Parkinson’s disease.

In a previous update, Yumanity said the preliminary results for Phase 1a study for YTX-7739 in patients with Parkinson’s disease are expected by mid-2021.

Now read: 4D Molecular starts dosing in early stage 4D-310 Fabry disease trial

[park_bear]

Their most recent published study can be found here:

ncbi.nlm.nih.gov/pmc/articl...

They used the good mouse model - mice that produce defective alpha synuclein and actually do get Parkinson's.

This is a long way from approval - 10 years is the average from preclinical stage to approval. That said they are doing it right so far.

[MissRita in reply to park_bear]

👏👏👏👏👏👏👏👏